Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety With Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease
2023-507766-35-00Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of vedolizumab in autoimmune colitis and Crohn's disease, sponsored by Takeda. Primary endpoint: Percentage of subjects with treatment-emergent adverse events (TEAEs). Started Mar 2024; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on 2023-507766-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507766-35-00.